Literature DB >> 5780204

Studies on the purification of antihemophilic factor (factor VIII). II. Separation of partially purified antihemophilic factor by gel filtration of plasma.

O D Ratnoff, L Kass, P D Lang.   

Abstract

A high degree of purification of antihemophilic factor was achieved by filtration of chylomicronpoor human plasma through columns of agarose. The final product contained, on the average, 67 units of antihemophilic activity per mg of protein, and was 3360-fold purified compared with the filtered plasma. The molecular weight of antihemophilic factor appeared to be at least two million. Preparations separated by gel filtration were contaminated with appreciable amounts of plasma thromboplastin antecedent (PTA), and traces of Christmas factor and Hageman factor, but no detectable fibrinogen was present. Similar fractions of plasma prepared from the blood of patients with classic hemophilia, von Willebrand's disease, or a circulating anticoagulant directed against antihemophilic factor contained, on the average, somewhat less protein than normal plasma; whether this difference was significant is not yet known. The purified fractions were partially stabilized by the addition of 1% gelatin. Adaptation of the technique of gel filtration to purification of antihemophilic factor for clinical use remains to be explored.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5780204      PMCID: PMC322305          DOI: 10.1172/JCI106055

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  4 in total

1.  An improved technique of agar-gel electrophoresis on microscope slides.

Authors:  R J WIEME
Journal:  Clin Chim Acta       Date:  1959-05       Impact factor: 3.786

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Production of high-potency concentrates of antihemophilic globulin in a closed-bag system.

Authors:  J G Pool; A E Shannon
Journal:  N Engl J Med       Date:  1965-12-30       Impact factor: 91.245

4.  Studies on the purification of antihemophilic factor (factor 8. I. Precipitation of antihemophilic factor by concanavalin A.

Authors:  L Kass; O D Ratnoff; M A Leon
Journal:  J Clin Invest       Date:  1969-02       Impact factor: 14.808

  4 in total
  11 in total

1.  The effects of epinephrine infusion in patients with von Willebrand's disease.

Authors:  F R Rickles; L W Hoyer; M E Rick; D J Ahr
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

2.  Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

Review 3.  Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.

Authors:  Yoshihiro Fujimura; Masanori Matsumoto; Hideo Yagi; Akira Yoshioka; Taei Matsui; Koiti Titani
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

4.  Nature of von Willebrand factor: a new assay and a specific inhibitor.

Authors:  K E Sarji; R D Stratton; R H Wagner; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

5.  The subunit structure of normal and hemophilic factor VIII.

Authors:  G A Shapiro; J C Andersen; S V Pizzo; P A McKee
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

6.  Factor VIII recombination after dissociation by CaCl12.

Authors:  H A Cooper; T R Griggs; R H Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1973-08       Impact factor: 11.205

7.  Genetic variants of von Willebrand's disease.

Authors:  L Holmberg; I M Nilsson
Journal:  Br Med J       Date:  1972-08-05

8.  Some effects of calcium on the activation of human factor VIII/Von Willebrand factor protein by thrombin.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

9.  Studies on the purification and characterization of human factor 8.

Authors:  S L Marchesi; N R Shulman; H R Gralnick
Journal:  J Clin Invest       Date:  1972-08       Impact factor: 14.808

10.  The defect in hemophilic and von Willebrand's disease plasmas studied by a recombination technique.

Authors:  H A Cooper; R H Wagner
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.